Mass balance study of [14C]SHR0302, a selective and potent JAK1 inhibitor in humans
Sign Up to like & getrecommendations! Published in 2023 at "Xenobiotica"
DOI: 10.1080/00498254.2023.2176267
Abstract: Abstract SHR0302, a selective JAK1 inhibitor developed by Jiangsu Hengrui Pharmaceutical Co., was intended for the treatment of rheumatoid arthritis. In this study, we evaluated the pharmacokinetics, mass balance, and metabolism of SHR0302 in six… read more here.
Keywords: 14c shr0302; mass balance; jak1 inhibitor; shr0302 selective ... See more keywords